CSL Limited Publishes First Corporate Responsibility Report


<p><span class="xn-location">MELBOURNE</span>, <span class="xn-location">Australia</span>, <span class="xn-chron">March 29</span> /CNW/ -- CSL Limited (ASX: CSL), Australia's leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company's economic, social and environmental performance for 2009.</p>
<p>"CSL has experienced significant growth over the past 10 years, which has been underpinned by our commitment to conducting our business ethically and actively contributing to the well-being of our communities," said <span class="xn-person">Dr. Brian McNamee</span>, CEO and Managing Director of CSL Limited. "Our first Corporate Responsibility Report is an important demonstration of this ongoing commitment."</p>
<p>The report details CSL's approach to and performance in key areas of corporate responsibility. These include the Company's research into new medicines, its ongoing success in ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for CSL employees, behaving responsibly in the global marketplace, and providing charitable support for communities in need around the world, while minimising the environmental impacts of its operations.</p>

    Highlights and statistics from some of these key areas include:
    --  The launch of the Company's Code of Responsible Business Practice,
        setting out the standards of conduct expected of CSL employees and
        business partners
    --  Continued investment totaling A$312 million in the research and
        development of protein-based medicines for the prevention and
        of rare and serious human illnesses
    --  A 26 percent increase in economic value distributed to the communities
        in which CSL operates, supported by 10 percent growth in the Company's
    --  Reduction of the Company's net water consumption by six percent at its
        manufacturing sites and the continued improvement of environmental
        intensity rates
    --  The contribution of nearly US$10 million to patient organisations in
        the Company's therapeutic areas and the announcement of new support
        access programs in developing countries

<p>"As a global company, CSL recognises its role in responding to humanitarian emergencies around the world, from pandemics to earthquakes," said <span class="xn-person">Dr. McNamee</span>.</p>
<p>"Our support programs in developing countries help address pressing healthcare issues in our areas of expertise."</p>
<p>In 2009, CSL announced a US$3 million partnership with the World Federation of Hemophilia and pledged 3 million doses of pandemic H1N1 influenza vaccine to the World Health Organization. CSL also commissioned a study of antivenom access in <span class="xn-location">Papua New Guinea</span> and invested in new programs to help foster the next generation of medical researchers.</p>

    About CSL

<p>The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies.</p>
<p>With major facilities in <span class="xn-location">Australia</span>, <span class="xn-location">Germany</span>, <span class="xn-location">Switzerland</span> and the US, CSL has more than 11,000 employees working in 27 countries.</p>
<p>For more information about CSL Limited and its 2009 Corporate Responsibility Report, visit <a href="http://www.csl.com.au">www.csl.com.au</a>.</p>

<p> </p>
<p> </p>
    For further information please contact:
    Sharon McHale
    Corporate Responsibility Director
    CSL Limited
    Tel: +61 409 978 314


For further information: For further information: Sharon McHale, Corporate Responsibility Director, CSL Limited, Tel: +61-409-978-314 Web Site: http://www.csl.com.au

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890